Atrion Corporation (ATRI): Price and Financial Metrics

Atrion Corporation (ATRI): $313.14

5.46 (-1.71%)

POWR Rating

Component Grades








ATRI Price/Volume Stats

Current price $313.14 52-week high $705.74
Prev. close $318.60 52-week low $274.98
Day low $313.14 Volume 1,229
Day high $313.15 Avg. volume 4,269
50-day MA $348.13 Dividend yield 2.78%
200-day MA $508.32 Market Cap 551.13M

ATRI Stock Price Chart Interactive Chart >


  • Stability is the dimension where ATRI ranks best; there it ranks ahead of 67.72% of US stocks.
  • The strongest trend for ATRI is in Growth, which has been heading up over the past 177 days.
  • ATRI's current lowest rank is in the Growth metric (where it is better than 10.45% of US stocks).

ATRI Stock Summary

  • ATRI's went public 37.95 years ago, making it older than 93.02% of listed US stocks we're tracking.
  • Price to trailing twelve month operating cash flow for ATRI is currently 61.89, higher than 95.01% of US stocks with positive operating cash flow.
  • ATRI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 9.47% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ATRION CORP are LNN, SHYF, INTT, LIQT, and NTIC.
  • ATRI's SEC filings can be seen here. And to visit ATRION CORP's official web site, go to

ATRI Valuation Summary

  • In comparison to the median Healthcare stock, ATRI's EV/EBIT ratio is 76.38% higher, now standing at 22.4.
  • Over the past 243 months, ATRI's price/earnings ratio has gone up 8.4.

Below are key valuation metrics over time for ATRI.

Stock Date P/S P/B P/E EV/EBIT
ATRI 2023-11-20 3.2 2.2 25.1 22.4
ATRI 2023-11-17 3.1 2.2 24.6 22.0
ATRI 2023-11-16 3.1 2.1 24.2 21.6
ATRI 2023-11-15 3.0 2.1 23.9 21.3
ATRI 2023-11-14 3.4 2.4 26.7 23.8
ATRI 2023-11-13 3.2 2.3 25.4 22.7

ATRI Growth Metrics

    Its 3 year price growth rate is now at -27.84%.
  • Its 4 year revenue growth rate is now at 7.73%.
  • Its 4 year net income to common stockholders growth rate is now at 18.43%.
ATRI's revenue has moved up $25,878,000 over the prior 33 months.

The table below shows ATRI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 180.944 38.92 34.813
2022-06-30 179.168 41.107 34.251
2022-03-31 172.979 43.241 33.827
2021-12-31 165.009 38.798 33.055
2021-09-30 156.96 39.046 32.297
2021-06-30 147.89 35.575 31.263

ATRI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATRI has a Quality Grade of C, ranking ahead of 62.72% of graded US stocks.
  • ATRI's asset turnover comes in at 0.555 -- ranking 81st of 186 Medical Equipment stocks.
  • SMLR, FONR, and STXS are the stocks whose asset turnover ratios are most correlated with ATRI.

The table below shows ATRI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.555 0.426 0.167
2021-03-31 0.541 0.438 0.170
2020-12-31 0.562 0.448 0.184
2020-09-30 0.573 0.452 0.193
2020-06-30 0.596 0.457 0.217
2020-03-31 0.611 0.458 0.232

Atrion Corporation (ATRI) Company Bio

Atrion Corporation develops, manufactures, and sells fluid delivery devices, and ophthalmic and cardiovascular products for medical applications primarily in the United States, Canada, and internationally. The company was founded in 1944 and is based in Allen, Texas.

ATRI Latest News Stream

Event/Time News Detail
Loading, please wait...

ATRI Latest Social Stream

Loading social stream, please wait...

View Full ATRI Social Stream

Latest ATRI News From Around the Web

Below are the latest news stories about ATRION CORP that investors may wish to consider to help them evaluate ATRI as an investment opportunity.

Insider Buying: Atrion President & CEO Bought US$90k Of Shares

Whilst it may not be a huge deal, we thought it was good to see that the Atrion Corporation ( NASDAQ:ATRI ) President...

Yahoo | November 18, 2023

Atrion Reports Third Quarter 2023 Results

ALLEN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the third quarter ended September 30, 2023. Revenues for the third quarter of 2023 totaled $41.9 million compared to $44.6 million for the same period in 2022. For the quarter ended September 30, 2023, operating income was $4.1 million, down $5.5 million from the comparable 2022 period, and net income was $2.9 million, down $5.9 million from the same period in 2022. Third quarter 202

Yahoo | November 7, 2023

Returns On Capital At Atrion (NASDAQ:ATRI) Paint A Concerning Picture

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...

Yahoo | October 16, 2023

Atrion Corporation Announces Election of New Director

ALLEN, Texas, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) announced the election today of Jeannette Bankes as a director, effective immediately. Ms. Bankes brings to our Board over 32 years of experience at major medical device and pharmaceutical companies. Since March 2019, Ms. Bankes has served as the President and General Manager of the Global Surgical Franchise at Alcon Inc. From August 2004 to March 2019, Ms. Bankes served in leadership positions across multiple div

Yahoo | September 20, 2023

Atrion Corporation's (NASDAQ:ATRI) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

With its stock down 17% over the past three months, it is easy to disregard Atrion (NASDAQ:ATRI). However, the...

Yahoo | September 13, 2023

Read More 'ATRI' Stories Here

ATRI Price Returns

1-mo -6.33%
3-mo -32.98%
6-mo -42.95%
1-year -47.76%
3-year -48.77%
5-year -57.10%
YTD -42.90%
2022 -19.58%
2021 10.94%
2020 -13.63%
2019 2.16%
2018 18.45%

ATRI Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ATRI Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!